Skip to main content
 
  • Engineering any genome, at any site, in any way

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech

News

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

September 10, 2018
The interference proceeding remains terminated without any determination of inventorship on CRISPR/Cas9 genome editing technology or its application to eukaryotic cells   University of California/University of Vienna/Dr. Charpentier...

CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

June 19, 2018
Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...